DM1-2 iPAX7-hiPS cell line
Invented by Rita Perlingeiro Kyba
Invented at The University of Minnesota, Twin Cities
- References (1)
- Inventor Info
|Antigen/Gene or Protein Targets
|myotonic dystrophy protein kinase (DMPK)
|skin fibroblasts from a diagnosed DM1 patient
|Myotonic dystrophy 1 (DM-1)
|Myotonic dystrophy is a genetic disease characterized by a loss of muscle function. Myotonic dystrophy type 1 (DM1), the most common form of myotonia, is caused by mutations in the DMPK gene. Currently, there is no cure or treatment for DM1.
|To generate a cell-based model for DM1, researchers obtained a sample of skin fibroblasts from two diagnosed DM1 patients. These fibroblasts (DM1-1 and DM1-2) were reprogrammed to hiPS cells via the Sendai virus method. Following reprogramming, DM1-1 and DM1-2 hiPS cells were modified to express PAX7 under the presence of exogenous doxycycline. Expression of PAX7 results in the differentiation of the DM1-1 and DM1-2 hiPSC cells into skeletal muscle cells. These differentiated muscle cells recapitulate similar characteristics of muscle cells from DM1 patients.
|Cell Signaling & Signal Transduction, Drug Discovery & Development
|4 total cell lines are available: 2 undifferentiated hiPSC lines from two DM1 patients (DM1-1 hiPS cell line, DM1-2 hiPS cell line) and 2 differentiated skeletal muscle cell lines (DM1-1 iPAX7-hiPS cell line and DM1-2 iPAX7-hiPS cell line).
There are 1 reference entries for this reagent.View All References
Rita Perlingeiro Kyba